The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Molecular Biomarker Analyses Using Circulating Tumor Cells
Open accessAbstract
BACKGROUND: Evaluation of cancer biomarkers from blood could significantly enable biomarker assessment by providing a relatively non-invasive source of representative tumor material. Circulating Tumor Cells (CTCs) isolated from blood of metastatic cancer patients hold significant promise in this regard. METHODOLOGY/PRINCIPAL FINDINGS: Using spiked tumor-cells we evaluated CTC capture on different CTC technology platforms, including CellSearch and two biochip platforms, and used the isolated CTCs to develop and optimize assays for molecular characterization of CTCs. We report similar performance for the various platforms tested in capturing CTCs, and find that capture efficiency is dependent on the level of EpCAM expression. We demonstrate that captured CTCs are amenable to biomarker analyses such as HER2 status, qRT-PCR for breast cancer subtype markers, KRAS mutation detection, and EGFR staining by immunofluorescence (IF). We quantify cell surface expression of EGFR in metastatic lung cancer patient samples. In addition, we determined HER2 status by IF and FISH in CTCs from metastatic breast cancer patients. In the majority of patients (89%) we found concordance with HER2 status from patient tumor tissue, though in a subset of patients (11%), HER2 status in CTCs differed from that observed in the primary tumor. Surprisingly, we found CTC counts to be higher in ER+ patients in comparison to HER2+ and triple negative patients, which could be explained by low EpCAM expression and a more mesenchymal phenotype of tumors belonging to the basal-like molecular subtype of breast cancer. CONCLUSIONS/SIGNIFICANCE: Our data suggests that molecular characterization from captured CTCs is possible and can potentially provide real-time information on biomarker status. In this regard, CTCs hold significant promise as a source of tumor material to facilitate clinical biomarker evaluation. However, limitations exist from a purely EpCAM based capture system and addition of antibodies to mesenchymal markers could further improve CTC capture efficiency to enable routine biomarker analysis from CTCs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“HER2 gene amplification status by fluorescence in situ hybridization (FISH) assay is routinely used to determine patient eligibility for anti-HER2 therapies such as trastuzumab and lapatinib [39,40,41].”
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Cristofanilli, M., Budd, G. T., Ellis, M. J., Stopeck, A., Matera, J., Miller, M. C., Reuben, J. M., Doyle, G. V., Allard, W. J., Terstappen, L. W. M. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040766 · Cited by 4,593
Wolff, A. C., Hammond, M. E. H., Schwartz, J. N., Hagerty, K. L., Allred, D. C., Cote, R. J., Dowsett, M., Fitzgibbons, P. L., Hanna, W. M., Langer, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2775 · Cited by 4,434
Isolation of rare circulating tumour cells in cancer patients by microchip technology
Nagrath, S., Sequist, L. V., Maheswaran, S., Bell, D. W., Irimia, D., Ulkus, L., Smith, M. R., Kwak, E. L., Digumarthy, S., Muzikansky, A., et al. (2007) · Nature · doi:10.1038/nature06385 · Cited by 3,559
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes
Neve, R. M., Chin, K., Fridlyand, J., Yeh, J., Baehner, F. L., Fevr, T., Clark, L., Bayani, N., Coppe, J.-P., Tong, F., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.008 · Cited by 3,188
Allard, W. J., Matera, J., Miller, M. C., Repollet, M., Connelly, M. C., Rao, C., Tibbe, A. G. J., Uhr, J. W., & Terstappen, L. W. M. M. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0378 · Cited by 2,542 · cited 4×
“Furthermore, we found that even in a tumor type such as NSCLC, which has previously been reported to have a prevalence of only 20% of patients having any CTCs [18], we were able to capture at least one CTC and quantitate EGFR expression in blood samples from 24 out of 34 patients we evaluated.”
BackgroundMethodInfluentialde Bono, J. S., Scher, H. I., Montgomery, R. B., Parker, C., Miller, M. C., Tissing, H., Doyle, G. V., Terstappen, L. W. W. M., Pienta, K. J., & Raghavan, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0872 · Cited by 2,182
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Cohen, S. J., Punt, C. J. A., Iannotti, N., Saidman, B. H., Sabbath, K. D., Gabrail, N. Y., Picus, J., Morse, M., Mitchell, E., Miller, M. C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.8923 · Cited by 1,841
Detection of Mutations in EGFR in Circulating Lung-Cancer Cells
Maheswaran, S., Sequist, L. V., Nagrath, S., Ulkus, L., Brannigan, B., Collura, C. V., Inserra, E., Diederichs, S., Iafrate, A. J., Bell, D. W., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800668 · Cited by 1,617
Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer
Cristofanilli, M., Hayes, D. F., Budd, G. T., Ellis, M. J., Stopeck, A., Reuben, J. M., Doyle, G. V., Matera, J., Allard, W. J., Miller, M. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.140 · Cited by 1,135
Detection, clinical relevance and specific biological properties of disseminating tumour cells
Pantel, K., Brakenhoff, R. H., & Brandt, B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2375 · Cited by 1,118
Frequent EpCam protein expression in human carcinomas
Went, P. T. H., Lugli, A., Meier, S., Bundi, M., Mirlacher, M., Sauter, G., & Dirnhofer, S. (2004) · Human Pathology · doi:10.1016/j.humpath.2003.08.026 · Cited by 819
Miller, M. C., Doyle, G. V., & Terstappen, L. W. M. M. (2010) · Journal of Oncology · doi:10.1155/2010/617421 · Cited by 750
Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Bardelli, A., & Siena, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6116 · Cited by 746
Aktas, B., Tewes, M., Fehm, T., Hauch, S., Kimmig, R., & Kasimir-Bauer, S. (2009) · Breast Cancer Research · doi:10.1186/bcr2333 · Cited by 736
Natural History of Early, Localized Prostate Cancer
Johansson, J.-E. (2004) · JAMA · doi:10.1001/jama.291.22.2713 · Cited by 703
Sequist, L. V., Bell, D. W., Lynch, T. J., & Haber, D. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3585 · Cited by 624
Stott, S. L., Lee, R. J., Nagrath, S., Yu, M., Miyamoto, D. T., Ulkus, L., Inserra, E. J., Ulman, M., Springer, S., Nakamura, Z., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000403 · Cited by 539
Attard, G., Swennenhuis, J. F., Olmos, D., Reid, A. H. M., Vickers, E., A'Hern, R., Levink, R., Coumans, F., Moreira, J., Riisnaes, R., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3667 · Cited by 533 · cited 2×
“Another appealing facet of CTCs as a surrogate diagnostic tissue is the idea that CTCs could constitute a ‘‘liquid biopsy’’ and provide realtime information about the patient’s current disease state [24,25].”
BackgroundHER-2 gene amplification can be acquired as breast cancer progresses
Meng, S., Tripathy, D., Shete, S., Ashfaq, R., Haley, B., Perkins, S., Beitsch, P., Khan, A., Euhus, D., Osborne, C., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0402993101 · Cited by 508
Ross, A., Cooper, B., Lazarus, H., Mackay, W., Moss, T., Ciobanu, N., Tallman, M., Kennedy, M., Davidson, N., & Sweet, D. (1993) · Blood · doi:10.1182/blood.v82.9.2605.2605 · Cited by 488
Talasaz, A. H., Powell, A. A., Huber, D. E., Berbee, J. G., Roh, K.-H., Yu, W., Xiao, W., Davis, M. M., Pease, R. F., Mindrinos, M. N., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813188106 · Cited by 480
Suzuki, H., Freije, D., Nusskern, D. R., Okami, K., Cairns, P., Sidransky, D., Isaacs, W. B., & Bova, G. S. (1998) · PubMed · Cited by 452
McCarty, K. S., Szabo, E. M., Flowers, J. L., Cox, E. B., Leight, G. S., Miller, L. A., Konrath, J. G., Jt, S., Budwit, D. A., & Wt, C. (1986) · PubMed · Cited by 417
Circulating Tumor Cell as a Diagnostic Marker in Primary Lung Cancer
Tanaka, F., Yoneda, K., Kondo, N., Hashimoto, M., Takuwa, T., Matsumoto, S., Okumura, Y., Rahman, S., Tsubota, N., Tsujimura, T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1095 · Cited by 333
Momburg, F., Moldenhauer, G., Hämmerling, G. J., & Möller, P. (1987) · PubMed · Cited by 328
Circulating tumor cells: a window into cancer biology and metastasis
Maheswaran, S., & Haber, D. A. (2010) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.12.002 · Cited by 316
Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites
Gancberg, D., Di Leo, A., Cardoso, F., Rouas, G., Pedrocchi, M., Paesmans, M., Verhest, A., Bernard-Marty, C., Piccart, M. J., & Larsimont, D. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf252 · Cited by 309
Circulating tumor cells (CTCs): Detection methods and their clinical relevance in breast cancer
Mostert, B., Sleijfer, S., Foekens, J. A., & Gratama, J. W. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.03.004 · Cited by 282
Zidan, J., Dashkovsky, I., Stayerman, C., Basher, W., Cozacov, C., & Hadary, A. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602738 · Cited by 282
Genetic Heterogeneity in HER2 Testing in Breast Cancer: Panel Summary and Guidelines
Vance, G. H., Barry, T. S., Bloom, K. J., Fitzgibbons, P. L., Hicks, D. G., Jenkins, R. B., Persons, D. L., Tubbs, R. R., & Hammond, M. E. H. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.4.611 · Cited by 239
Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer Subtypes
Hu, X., Stern, H. M., Ge, L., O'Brien, C., Haydu, L., Honchell, C. D., Haverty, P. M., Peters, B. A., Wu, T. D., Amler, L. C., et al. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0107 · Cited by 217
Self-citationPestrin, M., Bessi, S., Galardi, F., Truglia, M., Biggeri, A., Biagioni, C., Cappadona, S., Biganzoli, L., Giannini, A., & Di Leo, A. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0461-7 · Cited by 201
de Bono, J. S., Attard, G., Adjei, A., Pollak, M. N., Fong, P. C., Haluska, P., Roberts, L., Melvin, C., Repollet, M., Chianese, D., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0268 · Cited by 192
The CTC-Chip: An Exciting New Tool to Detect Circulating Tumor Cells in Lung Cancer Patients
Sequist, L. V., Nagrath, S., Toner, M., Haber, D. A., & Lynch, T. J. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181989565 · Cited by 189
Hicks, D. G., & Tubbs, R. R. (2005) · Human Pathology · doi:10.1016/j.humpath.2004.11.010 · Cited by 173
Biomarker-Driven Early Clinical Trials in Oncology: A Paradigm Shift in Drug Development
Tan, D. S. W., Thomas, G. V., Garrett, M. D., Banerji, U., de Bono, J. S., Kaye, S. B., & Workman, P. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181bd0445 · Cited by 171
Flores, L. M., Kindelberger, D. W., Ligon, A. H., Capelletti, M., Fiorentino, M., Loda, M. F., Cibas, E. S., Janne, P. A., & Krop, I. E. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605676 · Cited by 137
Mechanisms, Hypotheses and Questions Regarding Prostate Cancer Micrometastases to Bone
Lange, P. H., & Vessella, R. L. (1998) · Cancer and Metastasis Reviews · doi:10.1023/a:1006106209527 · Cited by 118
O'Brien, C. L., Cavet, G., Pandita, A., Hu, X., Haydu, L. E., Mohan, S., Toy, K. J., Rivers, C. S., Modrusan, Z. D., Amler, L. C., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0234 · Cited by 112
Self-citationMonitoring Drug-Induced γH2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells
Wang, L. H., Pfister, T. D., Parchment, R. E., Kummar, S., Rubinstein, L., Evrard, Y. A., Gutierrez, M. E., Murgo, A. J., Tomaszewski, J. E., Doroshow, J. H., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2799 · Cited by 106
Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E
Jarry, A., Masson, D., Cassagnau, E., Parois, S., LABOISSE, C. L., & Denis, M. G. (2004) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2004.05.004 · Cited by 97
Smith, G. D., Chadwick, B. E., Willmore‐Payne, C., & Bentz, J. S. (2007) · Journal of Clinical Pathology · doi:10.1136/jcp.2007.051425 · Cited by 92
Carden, C. P., Sarker, D., Postel-Vinay, S. C., Yap, T. A., Attard, G., Banerji, U., Garrett, M. D., THOMAS, G. V., Workman, P., Kaye, S. B., et al. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.11.006 · Cited by 88
Payne, R., Yagüe, E., Slade, M. J., Apostolopoulos, C., Jiao, L. R., Ward, B., Coombes, R. C., & Stebbing, J. (2008) · Pharmacogenomics · doi:10.2217/14622416.10.1.51 · Cited by 69
Bozzetti, C., Personeni, N., Nizzoli, R., Guazzi, A., Flora, M., Bassano, C., Negri, F., Martella, E. M., Naldi, N., Franciosi, V., et al. (2003) · Cancer · doi:10.1002/cncr.11731 · Cited by 44
Prospects for personalized medicine with inhibitors targeting the RAS and PI3K pathways
Lackner, M. R. (2009) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.09.78 · Cited by 20
Self-citation
Cited by
Challenges in circulating tumour cell research
Alix-Panabières, C., & Pantel, K. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3820 · Cited by 1,300
Isolation and retrieval of circulating tumor cells using centrifugal forces
Hou, H. W., Warkiani, M. E., Khoo, B. L., Li, Z. R., Soo, R. A., Tan, D. S.-W., Lim, W.-T., Han, J., Bhagat, A. A. S., & Lim, C. T. (2013) · Scientific Reports · doi:10.1038/srep01259 · Cited by 736
Gorges, T. M., Tinhofer, I., Drosch, M., Röse, L., Zollner, T. M., Krahn, T., & von Ahsen, O. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-178 · Cited by 565
Wood, S. L., Pernemalm, M., Crosbie, P. A., & Whetton, A. D. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.10.001 · Cited by 485
Punnoose, E. A., Atwal, S., Liu, W., Raja, R., Fine, B. M., Hughes, B. G. M., Hicks, R. J., Hampton, G. M., Amler, L. C., Pirzkall, A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3148 · Cited by 415
“We have previously shown that the typical leukocyte range after capture is 1,000 to 3,000 cells (20), which might have”
BackgroundMethodInfluentialSelf-citation
Metadata
- Authors
- Punnoose, E. A., Atwal, S. K., Spoerke, J. M., Savage, H., Pandita, A., Yeh, R.-F., Pirzkall, A., Fine, B. M., Amler, L. C., Chen, D. S., & Lackner, M. R.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-09-08
- Volume
- 5
- Issue
- 9
- Pages
- e12517
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2023933362
- Cited by
- 294
- References
- 50
- FWCI
- 9.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.